Merkel cell carcinoma
Drug research and approvals for merkel cell carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 36 studies of merkel cell carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 36
- Trials authorized in Canada: 5
- FDA orphan approvals: 3
- EU medicines: 1
Recruiting Now
Newest start dates first, of 36 recruiting on ClinicalTrials.gov ↗- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586 · Phase 1 / Phase 2 · Arvinas Inc. · starts Jul 29, 2026
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With…NCT07600476 · Phase 1 · Kupando GmbH · starts Jul 3, 2026
- A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult…NCT07302347 · Phase 1 / Phase 2 · Merck Sharp & Dohme LLC · starts Jun 23, 2026
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabNCT07387198 · Phase 2 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · starts May 29, 2026
- TIL Therapy in cSCC and MCCNCT07288073 · Phase 2 · Karam Khaddour, MD, MS · starts Feb 10, 2026
- Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyNCT07215988 · Not reported · Ohio State University Comprehensive Cancer Center · starts Feb 4, 2026
- IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)NCT06940440 · Phase 1 · TuHURA Biosciences, Inc. · starts Jan 27, 2026
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve…NCT07285044 · Phase 2 · Mayo Clinic · starts Dec 18, 2025
- Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With…NCT06947928 · Phase 2 / Phase 3 · TuHURA Biosciences, Inc. · starts Dec 11, 2025
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsNCT07006727 · Phase 1 · Novartis Pharmaceuticals · starts Oct 16, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 24, 2024 | A randomized phase 2 study of atr inhibition in advanced pd-(l)1-refractory merkel cell carcinoma: the matrix trialTUVUSERTIB (M1774) / AVELUMAB | UNIVERSITY HEALTH NETWORK | Ongoing |
| Nov 9, 2021 | A phase 1b/2, open-label study evaluating the safety and efficacy ofkrt-232 in patients with p53 wild-type (p53wt) merkel cell carcinoma (mcc) who have failed…NAVTEMADLIN (KRT-232) / AVELUMAB | KARTOS THERAPEUTICS INC | Ongoing |
| Nov 26, 2018 | A phase 3 open-label, single arm study to evaluate the safety and efficacy of pembrolizumab (mk-3475) as first-line therapy in participants with advanced…KEYTRUDA | Merck & Co. (MSD) | Ongoing |
| Oct 17, 2018 | A phase 2 study of incmga00012 in participants with metastatic merkel cell carcinomaINCMGA00012 (MGA012) | Incyte Corporation | Closed |
| May 24, 2017 | A phase II, open-label, multicenter trial to investigate the clinical activiity and safety of avelumab (msb0010718c) in subjects with merkel cell carcinomaMSB0010718C (AVELUMAB) | Merck KGaA | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 22, 2023 | Zynyztreatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) | Incyte Corporation | Approved |
| Dec 19, 2018 | KeytrudaKEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma | MSD International Business GmbH | Approved |
| Mar 23, 2017 | BavencioTreatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma | EMD Serono Research and Development Institute, Inc. | Approved |
| Mar 21, 2024 | topotecan liposome injectionTreatment of Merkel Cell Carcinoma | Fujifilm Pharmaceuticals U.S.A., Inc. | Designated |
| Oct 17, 2022 | bi-specific fragment crystallizable region (Fc) fusion…Treatment of Merkel cell carcinoma | GI Innovation, Inc. | Designated |
| Mar 1, 2021 | cavrotolimodTreatment of merkel cell carcinoma | Exicure, Inc. | Designated |
| Apr 8, 2020 | navtemadlinTreatment of Merkel cell carcinoma | Kartos Therapeutics, Inc. | Designated |
| Mar 15, 2017 | activated natural killer[aNK])Treatment of Merkel cell carcinoma | ImmunityBio, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 18, 2017 | Bavencioavelumab | Merck Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA